New therapeutic strategies for refractory ovarian cancer with molecular targeted drugs targeting EpCAM-positive cancer stem cells
The molecular biology behind ovarian cancer remains lacking. Currently, there are few reliable treatments and biomarkers. This cancer is particularly lethal as there are few symptoms when the cancer starts to metastasise. At this point, treatment effectiveness is dramatically reduced and survival rates are low. Motohara and a team of researchers at the Department of Obstetrics and Gynecology are working to identify the molecular mechanisms behind ovarian cancer. 'Our research is focused on understanding the molecular mechanisms of evolution of ovarian cancer, especially the biology of ovarian cancer stem cells regarding metastasis and chemoresistance, and on the development of novel therapeutic strategies for ovarian cancer,' he says. 'Ultimately, we hope that ovarian cancer treatments directed toward the eradication of the subpopulation of ovarian cancer stem cells will lead to higher survival rates and brighter prognoses for patients.'
The focus of Motohara and his colleagues' work are two prominent cell surface markers epithelial cell adhesion molecule (EpCAM) and CD44v6. EpCAM is normally involved in cell adhesion in epithelial tissues but a simple cleavage of the protein can cause part of it to remain inside the cell and cause havoc with gene expression, promoting tumour growth. CD44 is an important protein for fundamental cell functions such as cell-cell interactions, migration and adhesion. However, a variant known as CD44v6 can be produced through RNA splicing that allows the protein's properties to be harnessed by the cancer stem cell. This greatly aids the cancer's ability to migrate and establish growth on different tissues and is therefore a key part of the metastatic events that are the primary cause of lethality.
Keywords: ANTI-CANCER THERAPEUTICS; BIOMARKERS; CANCER; CANCER DIAGNOSTICS; CANCER STEM CELLS; CD44V6; CELL MEMBRANE; CELL SURFACE MARKERS; CELL-CELL INTERACTIONS; CHEMORESISTANCE; EPITHELIAL CELL ADHESION MOLECULE (EPCAM); EPITHELIAL TISSUES; EVOLUTION OF OVARIAN CANCER; GENETIC MUTATIONS; METASTASISE; MICROENVIRONMENT; MOLECULAR MECHANISMS; NOVEL THERAPEUTIC STRATEGIES FOR OVARIAN CANCER; OVARIAN CANCER; PROTEIN PATHWAYS; RNA SPLICING
Document Type: Research Article
Publication date: 01 December 2018
Impact is a series of high-quality, open access and free to access science reports designed to enable the dissemination of research impact to key stakeholders. Communicating the impact and relevance of research projects across a large number of subjects in a content format that is easily accessible by an academic and stakeholder audience. The publication features content from the world's leading research councils, policy groups, universities and research projects. Impact is published under a CC-BY Creative Commons licence.
- Subscribe to this Title
- Terms & Conditions
- Disseminating research in Impact
- Information about Impact
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content